ReviewObesity reviews : an official journal of the International Association for the Study of Obesity2026
CD36 and Its Role in Obesity.
Review in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Chronic choline restriction remodels hepatic lipid metabolism and drives insulin resistance through a CD36-ETNPPL regulatory axis.Molecular metabolism · 2026Article
- Study of CD36 receptor gene expression in obese and non-obese chronic kidney disease patients.Molecular biology reports · 2026Article
- Licochalcone E Ameliorates Hepatic Steatosis in Obese Mice by Activating the Sirt1/AMPK Pathway and Reducing Hepatic Lipid Accumulation.Biomolecules & therapeutics · 2026Article
- Altered Lipid Profile and Oxidative Stress During Pregnancy: Impact on the Fetus and Risk of Metabolic Disorders in Adulthood.International journal of molecular sciences · 2026Review
- Circulating Liver-Derived and CD36Journal of extracellular vesicles · 2026Article
- CD36 and Its Role in Obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Obesity is understood as a condition driven by interactions between genetics and environmental factors. The role of CD36 in the regulation of lipid metabolism and ectopic fat accumulation emerges as a key area of interest. This review presents CD36 not only as a crucial facilitator of fatty acid uptake but also as a regulator of how and where excess lipids are stored. Ectopic fat accumulation-lipid deposition in non-adipose tissues such as the liver, muscle, and pancreas-is linked to obesity-related complications, including metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular risk. Through CD36, tissues that normally play minor roles in lipid storage become overloaded, leading to metabolic dysfunction. We offer a fresh perspective on the adipose tissue expandability hypothesis, positioning CD36 as a regulator of adipose tissue's capacity to store lipids. Possibly, once adipose tissue reaches its expansion limit, CD36-mediated mechanisms drive the spillover of lipids into ectopic sites, exacerbating obesity complications. This insight offers a transformative view of CD36 as a player in the metabolic tipping point between healthy fat storage and pathogenic fat deposition. The connection between CD36 and extracellular vesicles (EVs) hints at a broader network of inter-tissue communication that could further amplify ectopic fat accumulation. Finally, we list evidence showing how CD36 genetics are related to the predisposition to develop and manage obesity. By understanding the role of CD36 in fat storage regulation, new personalized therapeutic strategies may emerge, targeting its pathways to prevent or reverse the metabolic damage caused by ectopic fat.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.